4.45
Schlusskurs vom Vortag:
$4.44
Offen:
$4.55
24-Stunden-Volumen:
286.07K
Relative Volume:
1.04
Marktkapitalisierung:
$141.97M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+12.37%
1M Leistung:
+12.66%
6M Leistung:
-77.85%
1J Leistung:
+0.00%
Bioage Labs Inc Stock (BIOA) Company Profile
Firmenname
Bioage Labs Inc
Sektor
Telefon
510-806-1445
Adresse
1445A SOUTH 50TH STREET, RICHMOND
Vergleichen Sie BIOA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
BIOA
Bioage Labs Inc
|
4.45 | 141.97M | 0 | 0 | 0 | 0.00 |
![]()
ZTS
Zoetis Inc
|
170.16 | 75.08B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
11.07 | 51.07B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 46.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.77 | 19.24B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
325.82 | 14.38B | 2.99B | 1.21B | 1.13B | 25.06 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
2024-12-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
2024-12-09 | Herabstufung | Citigroup | Buy → Neutral |
2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
2024-10-21 | Eingeleitet | Citigroup | Buy |
2024-10-21 | Eingeleitet | Jefferies | Buy |
2024-10-21 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioage Labs Inc Aktie (BIOA) Neueste Nachrichten
Lead Plaintiff Appointed in BioAge Labs Class Action — Here’s How You Can Recover Your Losses - TradingView
BioAge Labs, Inc. Announces Updates on APJ Agonist Program Updates - marketscreener.com
BioAge Labs Updates Milestones for NLRP3 Program - TipRanks
Bioage advances apelin receptor agonist program with option to Jikang’s nanobody - BioWorld MedTech
BioAge deepens weight loss R&D with fresh apelin receptor push - The Pharma Letter
BioAge Labs expands APJ agonist pipeline with biologic candidates - TipRanks
BioAge Labs Enters Option Agreement with JiKang Therapeutics to In-License Novel APJ Agonist Antibody and Expands Intellectual Property for Small Molecule APJ Agonists - Nasdaq
BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates - The Manila Times
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK) and BioAge Labs, Inc. (BIOA) - The Globe and Mail
Bioage plans mid-year IND submission for BGE-102 for obesity - BioWorld MedTech
BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic - Pipelinereview
BioAge advances obesity drug into clinical trials By Investing.com - Investing.com South Africa
BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 - Insider Monkey
Jefferies maintains hold on BioAge Labs with $4 target By Investing.com - Investing.com India
Jefferies maintains hold on BioAge Labs with $4 target - Investing.com
BioAge Labs, Inc. Completes IND-enabling Studies for BGE-102 - marketscreener.com
BioAge advances obesity drug into clinical trials - Investing.com Australia
BioAge Labs completes IND-enabling studies for BGE-102, a - GlobeNewswire
BioAge Labs to Present at Upcoming Investor Conferences - The Manila Times
BioAge Labs Announces Major Investor Presentations: Key Updates Expected at Global Healthcare Conferences - Stock Titan
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Class Action Filed Against BioAge Labs, Inc. (BIOA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
BioAge Leaders Touted Obesity Drug Before Safety Woes, Suit Says - Bloomberg Law News
Invitation to presentation of BioArctic's first quarter report for JanuaryMarch 2025 on May 21 at 9.30 a.m. CET - Stock Titan
Investors who Lost Money on BioAge Labs, Inc. (BIOA) Should Contact Levi & Korsinsky About Pending Class ActionBIOA - ACCESS Newswire
Cautious Outlook on BioAge Labs, Inc. Amid Program Setbacks and Financial Concerns - TipRanks
Lost Money on BioAge Labs, Inc. (BIOA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc.(BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of BioAge Labs, Inc. (BIOA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Levi & Korsinsky Notifies BioAge Labs, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineBIOA - ACCESS Newswire
Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – BIOA - ACCESS Newswire
Levi & Korsinsky Reminds BioAge Labs, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsBIOA - ACCESS Newswire
BioAge Labs Advances Pipeline with Strategic Collaborations - TipRanks
BioAge Labs, Inc Q1 Loss Narrows - Nasdaq
BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
With 44% stake, BioAge Labs, Inc. (NASDAQ:BIOA) seems to have captured institutional investors' interest - Yahoo Finance
BioAge Labs, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsBIOA - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR DEADLINE MONDAY: BioAge Labs, Inc. Investors with Subst - GuruFocus
Investors who lost money on BioAge Labs, Inc. should contact Levi & Korsinsky about an ongoing investigationBIOA - ACCESS Newswire
BioAge Labs, Inc. Being Investigated on Behalf of BioAge Labs, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
Investors who hold shares of BioAge Labs, Inc. (NASDAQ: BIOA) - openPR.com
Notice to Long-Term Shareholders of BioAge Labs, Inc. - GlobeNewswire
Notice to Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); Driven Bands Holdings - Bluefield Daily Telegraph
Finanzdaten der Bioage Labs Inc-Aktie (BIOA)
Es liegen keine Finanzdaten für Bioage Labs Inc (BIOA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):